Search results
Results from the WOW.Com Content Network
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
The European Patent Office (EPO) [notes 1] is one of the two organs of the European Patent Organisation (EPOrg), the other being the Administrative Council. [4] The EPO acts as executive body for the organisation [5] [6] while the Administrative Council acts as its supervisory body [5] as well as, to a limited extent, its legislative body.
The European Patent Office (EPO [notes 1]) examines European patent applications and grants European patents under the European Patent Convention.Its headquarters are located at Munich, Germany, with a branch in Rijswijk (near The Hague, Netherlands), sub-offices in Berlin, Germany, and Vienna, Austria, and a "liaison bureau" in Brussels, Belgium.
Donati felt this work "opened the road to EPO . . . because blood doping was a trial to understand the role of EPO". [ 36 ] Dr. Michele Ferrari , a former student and protege of Conconi, [ 37 ] had a controversial interview mentioning the drug in 1994, just after his Gewiss–Ballan team had a remarkable performance in the La Flèche Wallonne race.
Fig. 1 Achieving maximum aerobic capacity. Blood doping is defined as the use of illicit products (e.g. erythropoietin (EPO), darbepoetin-alfa, hypoxia-inducible factor (HIF) stabilizers) and methods (e.g. increase aerobic capacity by maximizing the uptake of O 2) in order to enhance the O 2 transport of the body to the muscles.
A characteristic of European patent law as it stands today is that European patents granted by the European Patent Office (EPO), and patents granted by national patent offices are available, [3] and may possibly –if permitted by national law and, if so, to the extent permitted by national law [4] – co-exist within a given jurisdiction.
A: No, unlike HMO plans, EPO plans do not require you to get a referral to see a specialist, as long as the specialist is within the network. Q: What happens if I go out of network with an EPO?
Erythropoietin in neuroprotection is the use of the glycoprotein erythropoietin (Epo) for neuroprotection. Epo controls erythropoiesis, or red blood cell production. Erythropoietin and its receptor were thought to be present in the central nervous system according to experiments with antibodies that were subsequently shown to be nonspecific.